Efficacy and Safety of Solifenacin Plus Tamsulosin OCAS in Men with Voiding and Storage Lower Urinary Tract Symptoms: Results from a Phase 2, Dose-finding Study (SATURN)

European Urology

Volumn 64, Issue 3, 2013, Pages 398-407

  Van Kerrebroeck, Philip ^a   Haab, François ^b   Angulo, Javier C ^c   Vik, Viktor ^d   Katona, Ferenc ^e   Garcia Hernandez, Alberto ^f   Klaver, Monique ^f   Traudtner, Klaudia ^f   Oelke, Matthias ^g  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL TENON   (France)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^e Jósa András Hospital I   (Hungary)

^f Astellas Pharma Global Development   (Netherlands)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Lower urinary tract symptoms; OCAS; Overactive bladder; Solifenacin; Storage symptoms; Tamsulosin; Voiding symptoms

Indexed keywords

PLACEBO; SOLIFENACIN; TAMSULOSIN;

ADULT; ARTICLE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSURIA; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART DISEASE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION; MONOTHERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITIONAL DIZZINESS; PRIORITY JOURNAL; QUALITY OF LIFE; RETROGRADE EJACULATION; SAMPLE SIZE; THORAX PAIN; URINARY FREQUENCY; URINE FLOW RATE; URINE RETENTION; VERTIGO; XEROSTOMIA;

LOWER URINARY TRACT SYMPTOMS; OVERACTIVE BLADDER; SOLIFENACIN; STORAGE SYMPTOMS; TAMSULOSIN OCAS; VOIDING SYMPTOMS;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; EUROPE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; SULFONAMIDES; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINATION; URINATION DISORDERS; URODYNAMICS; UROLOGICAL AGENTS;

EID: 84881159782     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.031     Document Type: Article

References (18)

1. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology Web site. http://www.uroweb.org/gls/pdf/ 13-Male-LUTS-LR.pdf.
2. C.C. Sexton, K.S. Coyne, and Z.S. Kopp The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS BJU Int 103 Suppl 3 2009 12 23
3. S.V. Morant, K. Reilly, G.A. Bloomfield, and C. Chapple Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK Int J Clin Pract 62 2008 688 694
4. B.T. Helfand, R.M. Evans, and K.T. McVary A comparison of the frequencies of medical therapies for overactive bladder in men and women: Analysis of more than 7.2 million aging patients Eur Urol 57 2010 586 591
5. A. Athanasopoulos, C. Chapple, and C. Fowler The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: An update Eur Urol 60 2011 94 105
6. R. Cartwright, S. Srikrishna, L. Cardozo, and D. Robinson Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder BJU Int 107 2011 1612 1617
7. L.S. Matza, C.L. Thompson, J. Krasnow, J. Brewster-Jordan, T. Zyczynski, and K.S. Coyne Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) Neurourol Urodyn 24 2005 215 225
8. L. Cardozo, J. Mikulas, G. Amarenco, T. Drogendijk, and G. Compion Total urgency score (TUS) as a measure of frequency and urgency in SUNRISE Urology 76 Suppl 3a 2010 592
9. L. Cardozo, E. Hessdorfer, R. Milani, P. Arano, L. Dewilde, and M. Slack Solifenacin in the treatment of urgency and other symptoms of overactive bladder: Results from a randomized, double-blind, placebo-controlled, rising-dose trial BJU Int 102 2008 1120 1127
10. S.A. Kaplan Identification of the patient with enlarged prostate: Diagnosis and guidelines for management Osteopath Med Prim Care 1 2007 11
11. T.J. Wilt, R. Macdonald, and I. Rutks Tamsulosin for benign prostatic hyperplasia [withdrawn] Cochrane Database Syst Rev 2003 CD002081
12. D. Luo, L. Liu, P. Han, Q. Wei, and H. Shen Solifenacin for overactive bladder: A systematic review and meta-analysis Int Urogynecol J 23 2012 983 991
13. A. Athanasopoulos, K. Gyftopoulos, K. Giannitsas, J. Fisfis, P. Perimenis, and G. Barbalias Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study J Urol 169 2003 2253 2256
14. S.A. Kaplan, C.G. Roehrborn, E.S. Rovner, M. Carlsson, T. Bavendam, and Z. Guan Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial JAMA 296 2006 2319 2328
15. C. Chapple, S. Herschorn, P. Abrams, F. Sun, M. Brodsky, and Z. Guan Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers Eur Urol 56 2009 534 543
16. O. Yamaguchi, H. Kakizaki, and Y. Homma Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study Urology 78 2011 126 133
17. S.A. Kaplan, K. McCammon, R. Fincher, A. Fakhoury, and W. He Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency J Urol 182 2009 2825 2830
18. S.A. Kaplan, C.G. Roehrborn, J. Gong, F. Sun, and Z. Guan Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms BJU Int 109 2012 1831 1840